NEXGEL forms partnership with STADA to distribute OTC health products in North America starting mid-2024

NEXGEL, INC.

Partnership with STADA Arzneimittel AG, a European consumer health leader, for distribution and commercialization.
Product launch expected mid-2024; brings established European OTC products to North American consumers.
STADA reported 2022 group sales of EUR 3,797.2 million and EBITDA of EUR 884.7 million.
NEXGEL will leverage its hydrogel expertise and contract manufacturing for the partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.